Monitor the IPO pricing and closing — if successful, the $10.6M net proceeds will fund the stroke trial through key milestones but leave the migraine trial underfunded. The company's survival depends on this offering; failure to close would likely trigger a liquidity crisis. Watch for FDA updates on the PerFOrm trial (13 patients enrolled out of 500 target).
Executive Summary
Encore Medical filed Amendment No. 7 to its S-1 for an IPO of 3,000,000 shares at $5.00 per share, expected to raise approximately $10.6 million in net proceeds after expenses and a $2.0 million license fee to GB Sciences. The company is a pre-revenue (in the U.S.) structural heart device firm with a PFO closure device for stroke and migraine, holding CE Mark approval but no FDA clearance. As of June 30, 2026, it had only $79,771 in cash, a working capital deficit of $2.37 million, and an accumulated deficit of $7.43 million, with a going concern opinion from its auditor.
Key Financial Metrics
Key Facts
- IPO of 3,000,000 shares at $5.00 per share; gross proceeds $15.0 million, net proceeds ~$10.6 million after underwriting discounts, expenses, and $2.0 million license fee
- Revenue for FY2025 was $2,585,858 (up 21.1% YoY from $2,134,528), but H1 2026 revenue fell 44.8% to $557,395 due to focus on IPO fundraising
- Net loss of ($928,088) in FY2025 and ($610,965) in H1 2026; accumulated deficit of $7,429,933 as of June 30, 2026
- Cash balance of $79,771 and working capital deficit of $2,374,090 as of June 30, 2026; auditor included going concern opinion
- Proceeds allocated: ~$6.9M for stroke clinical trial, $500K for migraine trial, $1.2M sales/marketing, $1.75M debt repayment, remainder for working capital
- License Agreement with GB Sciences requires $2.0M cash and 1,000,000 shares upon IPO closing for AI-enabled patient selection technology
Financial Impact
IPO expected to raise ~$10.6M net, providing critical funding for ~18-24 months of clinical trials and debt repayment, but does not cover full migraine trial through FDA approval
Risk Factors
- Going concern risk — only $79,771 cash and $2.37M working capital deficit; IPO is essential for survival
- No FDA approval for U.S. sales; clinical trial enrollment (13 of 500 patients) is early stage and may face delays
- Customer concentration — three customers represent 90.8% of accounts receivable as of June 30, 2026
- Related-party concentration — $660,055 receivable from Cardia, Inc. tied to Iraq supply contract with collection uncertainty
- Immediate and substantial dilution — new investors will own 27.9% of post-IPO shares but contribute 59.6% of total consideration
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001104659-26-093252 |
| Document: tm2525595d27_ex5-1.htm | 0001104659-26-093252 |
| Document: tm2525595d27_ex10-10b.htm | 0001104659-26-093252 |
| Document: tm2525595d27_ex10-9b.htm | 0001104659-26-093252 |
| Document: tm2525595d27_ex10-8b.htm | 0001104659-26-093252 |
| Document: tm2525595d27_ex23-1.htm | 0001104659-26-093252 |
| Document: 0001104659-26-093252-index-headers.html | 0001104659-26-093252 |
| Document: 0001104659-26-093252-index.html | 0001104659-26-093252 |
| Document: 0001104659-26-093252.txt | 0001104659-26-093252 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | S-1/A | — | awaiting T+20 | — | — |
Aug 10, 2026 11w ago | S-1/A | — | awaiting T+20 | — | — |
Jul 1, 2026 16w ago | S-1/A | — | awaiting T+20 | — | — |
Apr 3, 2026 29w ago | S-1/A | — | awaiting T+20 | — | — |
Mar 24, 2026 30w ago | S-1/A | — | awaiting T+20 | — | — |
Mar 3, 2026 33w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers